TomegaVax Inc. is an immunotherapy company that uses a revolutionary vaccine technology platform to tackle unmet medical needs. The company is focused on developing vaccines and immunotherapies for chronic and recurring viral infections such as HIV, HPV, HBV, and HSV. Their platform provides a continuous low-level antigen presentation to maintain an active T-cell-mediated immune shield, which allows immune-based therapy to target previously untreatable diseases. TomegaVax's technology brings new hope to patients suffering from chronic and recurring viral infections.